Rena Yadlapati1, Michael F Vaezi1, Marcelo F Vela1, Stuart J Spechler1, Nicholas J Shaheen1, Joel Richter1, Brian E Lacy1, David Katzka1, Philip O Katz1, Peter J Kahrilas1, Prakash C Gyawali1, Lauren Gerson1, Ronnie Fass1, Donald O Castell1, Jenna Craft1, Luke Hillman1, John E Pandolfino1. 1. Anschutz Medical Campus, University of Colorado, Aurora, CO, USA. Vanderbilt Medical Center, Nashville, TN, USA. Mayo Clinic, Scottsdale, AZ, USA. Baylor Health Care System, Dallas, TX, USA. University of North Carolina, Chapel Hill, NC, USA. University of South Florida, Tampa, FL, USA. Dartmouth Hitchcock Medical Center, Lebanon, NH, USA. Mayo Clinic, Rochester, MN, USA. Weill Cornell Medical Center, New York, NY, USA. Northwestern University, Chicago, IL, USA. Washington University, St. Louis, MO, USA. California Pacific Medical Center, San Francisco, CA, USA. Metro Health Medical Center, Cleveland, OH, USA. Medical University of South Carolina, Charleston, SC, USA. University of Wisconsin, Madison, WI, USA.
Abstract
BACKGROUND: The aim of this study was to assess expert gastroenterologists' opinion on treatment for distinct gastroesophageal reflux disease (GERD) profiles characterized by proton pump inhibitor (PPI) unresponsive symptoms. METHODS: Fourteen esophagologists applied the RAND/UCLA Appropriateness Method to hypothetical scenarios with previously demonstrated GERD (positive pH-metry or endoscopy) and persistent symptoms despite double-dose PPI therapy undergoing pH-impedance monitoring on therapy. A priori thresholds included: esophageal acid exposure (EAE) time >6.0%; symptom-reflux association: symptom index >50% and symptom association probability >95%; >80 reflux events; large hiatal hernia: >3 cm. Primary outcomes were appropriateness of four invasive procedures (laparoscopic fundoplication, magnetic sphincter augmentation, transoral incisionless fundoplication, radiofrequency energy delivery) and preference for pharmacologic/behavioral therapy. RESULTS: Laparoscopic fundoplication was deemed appropriate for elevated EAE, and moderately appropriate for positive symptom-reflux association for regurgitation and a large hiatal hernia with normal EAE. Magnetic sphincter augmentation was deemed moderately appropriate for elevated EAE without a large hiatal hernia. Transoral incisionless fundoplication and radiofrequency energy delivery were not judged appropriate in any scenario. Preference for non-invasive options was as follows: H2RA for elevated EAE, transient lower esophageal sphincter relaxation inhibitors for elevated reflux episodes, and neuromodulation/behavioral therapy for positive symptom-reflux association. CONCLUSION: For treatment of PPI unresponsive symptoms in proven GERD, expert esophagologists recommend invasive therapy only in the presence of abnormal reflux burden, with or without hiatal hernia, or regurgitation with positive symptom-reflux association and a large hiatus hernia. Non-invasive pharmacologic or behavioral therapies are preferred for all other scenarios.
BACKGROUND: The aim of this study was to assess expert gastroenterologists' opinion on treatment for distinct gastroesophageal reflux disease (GERD) profiles characterized by proton pump inhibitor (PPI) unresponsive symptoms. METHODS: Fourteen esophagologists applied the RAND/UCLA Appropriateness Method to hypothetical scenarios with previously demonstrated GERD (positive pH-metry or endoscopy) and persistent symptoms despite double-dose PPI therapy undergoing pH-impedance monitoring on therapy. A priori thresholds included: esophageal acid exposure (EAE) time >6.0%; symptom-reflux association: symptom index >50% and symptom association probability >95%; >80 reflux events; large hiatal hernia: >3 cm. Primary outcomes were appropriateness of four invasive procedures (laparoscopic fundoplication, magnetic sphincter augmentation, transoral incisionless fundoplication, radiofrequency energy delivery) and preference for pharmacologic/behavioral therapy. RESULTS: Laparoscopic fundoplication was deemed appropriate for elevated EAE, and moderately appropriate for positive symptom-reflux association for regurgitation and a large hiatal hernia with normal EAE. Magnetic sphincter augmentation was deemed moderately appropriate for elevated EAE without a large hiatal hernia. Transoral incisionless fundoplication and radiofrequency energy delivery were not judged appropriate in any scenario. Preference for non-invasive options was as follows: H2RA for elevated EAE, transient lower esophageal sphincter relaxation inhibitors for elevated reflux episodes, and neuromodulation/behavioral therapy for positive symptom-reflux association. CONCLUSION: For treatment of PPI unresponsive symptoms in proven GERD, expert esophagologists recommend invasive therapy only in the presence of abnormal reflux burden, with or without hiatal hernia, or regurgitation with positive symptom-reflux association and a large hiatus hernia. Non-invasive pharmacologic or behavioral therapies are preferred for all other scenarios.
Authors: C P Gyawali; S Roman; A J Bredenoord; M Fox; J Keller; J E Pandolfino; D Sifrim; R Tatum; R Yadlapati; E Savarino Journal: Neurogastroenterol Motil Date: 2017-05-24 Impact factor: 3.598
Authors: Nikos Viazis; Anastasia Keyoglou; Alexandros K Kanellopoulos; George Karamanolis; John Vlachogiannakos; Konstantinos Triantafyllou; Spiros D Ladas; Dimitrios G Karamanolis Journal: Am J Gastroenterol Date: 2011-05-31 Impact factor: 10.864
Authors: Rena Yadlapati; Michael Tye; Laurie Keefer; Peter J Kahrilas; John E Pandolfino Journal: Am J Gastroenterol Date: 2017-09-12 Impact factor: 10.864
Authors: Zilla H Hussain; Emily E Henderson; Carla Maradey-Romerao; Nina George; Ronnie Fass; Brian E Lacy Journal: Clin Transl Gastroenterol Date: 2015-10-08 Impact factor: 4.488
Authors: Andrew J Gawron; Reginald Bell; Barham K Abu Dayyeh; F P Buckley; Kenneth Chang; Christy M Dunst; Steven A Edmundowicz; Blair Jobe; John C Lipham; Dan Lister; Marcia Irene Canto; Michael S Smith; Anthony A Starpoli; George Triadafilopoulos; Thomas J Watson; Erik Wilson; John E Pandolfino; Alexander Kaizer; Zoe Van De Voorde; Rena Yadlapati Journal: Gastrointest Endosc Date: 2020-01-31 Impact factor: 9.427
Authors: Philip O Katz; Kerry B Dunbar; Felice H Schnoll-Sussman; Katarina B Greer; Rena Yadlapati; Stuart Jon Spechler Journal: Am J Gastroenterol Date: 2022-01-01 Impact factor: 10.864
Authors: Leandi Krüger; Tiffany A Pridgen; Ellie R Taylor; Katherine S Garman; Anthony T Blikslager Journal: Am J Physiol Gastrointest Liver Physiol Date: 2020-02-18 Impact factor: 4.052
Authors: Bethany J Slater; Rebecca C Dirks; Sophia K McKinley; Mohammed T Ansari; Geoffrey P Kohn; Nirav Thosani; Bashar Qumseya; Sarah Billmeier; Shaun Daly; Catherine Crawford; Anne P Ehlers; Celeste Hollands; Francesco Palazzo; Noe Rodriguez; Arianne Train; Eelco Wassenaar; Danielle Walsh; Aurora D Pryor; Dimitrios Stefanidis Journal: Surg Endosc Date: 2021-07-19 Impact factor: 4.584
Authors: Rena Yadlapati; Peter J Kahrilas; Mark R Fox; Albert J Bredenoord; C Prakash Gyawali; Sabine Roman; Arash Babaei; Ravinder K Mittal; Nathalie Rommel; Edoardo Savarino; Daniel Sifrim; André Smout; Michael F Vaezi; Frank Zerbib; Junichi Akiyama; Shobna Bhatia; Serhat Bor; Dustin A Carlson; Joan W Chen; Daniel Cisternas; Charles Cock; Enrique Coss-Adame; Nicola de Bortoli; Claudia Defilippi; Ronnie Fass; Uday C Ghoshal; Sutep Gonlachanvit; Albis Hani; Geoffrey S Hebbard; Kee Wook Jung; Philip Katz; David A Katzka; Abraham Khan; Geoffrey Paul Kohn; Adriana Lazarescu; Johannes Lengliner; Sumeet K Mittal; Taher Omari; Moo In Park; Roberto Penagini; Daniel Pohl; Joel E Richter; Jordi Serra; Rami Sweis; Jan Tack; Roger P Tatum; Radu Tutuian; Marcelo F Vela; Reuben K Wong; Justin C Wu; Yinglian Xiao; John E Pandolfino Journal: Neurogastroenterol Motil Date: 2021-01 Impact factor: 3.598